Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Emily A. Blumberg is active.

Publication


Featured researches published by Emily A. Blumberg.


American Journal of Transplantation | 2004

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.

Carlos V. Paya; Atul Humar; Ed Dominguez; Kenneth Washburn; Emily A. Blumberg; Barbara D. Alexander; Richard B. Freeman; Nigel Heaton; Mark D. Pescovitz

We compared the efficacy and safety of valganciclovir with those of oral ganciclovir in preventing cytomegalovirus (CMV) disease in high‐risk seronegative solid organ transplant (SOT) recipients of organs from seropositive donors (D+/R‐). In this randomised, prospective, double‐blind, double‐dummy study, 364 CMV D+/R‐ patients received valganciclovir 900 mg once daily or oral ganciclovir 1000 mg three times a day (tid) within 10 days of transplant and continued through 100 days. CMV disease, plasma viremia, acute graft rejection, graft loss and safety were analyzed up to 6 and 12 months post‐transplant. Endpoint committee‐defined CMV disease developed in 12.1% and 15.2% of valganciclovir and ganciclovir patients, respectively, by 6 months, though with a difference in the relative efficacy of valganciclovir and ganciclovir between organs (i.e. an organ type‐treatment interaction). By 12 months, respective incidences were 17.2% and 18.4%, and the incidence of investigator‐treated CMV disease events was comparable in the valganciclovir (30.5%) and ganciclovir (28.0%) arms. CMV viremia during prophylaxis was significantly lower with valganciclovir (2.9% vs. 10.4%; p = 0.001), but was comparable by 12 months (48.5% valganciclovir vs 48.8% ganciclovir). Time‐to‐onset of CMV disease and to viremia were delayed with valganciclovir; rates of acute allograft rejection were generally lower with valganciclovir. Except for a higher incidence of neutropenia with valganciclovir (8.2%, vs 3.2% ganciclovir) the safety profile was similar for both drugs. Overall, once‐daily oral valganciclovir was as clinically effective and well‐tolerated as oral ganciclovir tid for CMV prevention in high‐risk SOT recipients.


American Journal of Transplantation | 2010

The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients

Atul Humar; Yvon Lebranchu; Flavio Vincenti; Emily A. Blumberg; Jeffrey D. Punch; Ajit P. Limaye; Daniel Abramowicz; Alan G. Jardine; Athina Voulgari; Jane Ives; Ingeborg A. Hauser; Patrick Peeters

Late‐onset cytomegalovirus (CMV) disease is a significant problem with a standard 3‐month prophylaxis regimen. This multicentre, double‐blind, randomized controlled trial compared the efficacy and safety of 200 days’ versus 100 days’ valganciclovir prophylaxis (900 mg once daily) in 326 high‐risk (D+/R–) kidney allograft recipients. Significantly fewer patients in the 200‐day group versus the 100‐day group developed confirmed CMV disease up to month 12 posttransplant (16.1% vs. 36.8%; p < 0.0001). Confirmed CMV viremia was also significantly lower in the 200‐day group (37.4% vs. 50.9%; p = 0.015 at month 12). There was no significant difference in the rate of biopsy‐proven acute rejection between the groups (11% vs. 17%, respectively, p = 0.114). Adverse events occurred at similar rates between the groups and the majority were rated mild‐to‐moderate in intensity and not related to study medication. In conclusion, this study demonstrates that extending valganciclovir prophylaxis (900 mg once daily) to 200 days significantly reduces the incidence of CMV disease and viremia through to 12 months compared with 100 days’ prophylaxis, without significant additional safety concerns associated with longer treatment. The number needed to treat to avoid one additional patient with CMV disease up to 12 months posttransplant is approximately 5.


The New England Journal of Medicine | 2010

Outcomes of Kidney Transplantation in HIV-Infected Recipients

Peter G. Stock; Burc Barin; Barbara Murphy; Douglas W. Hanto; Jorge Diego; Jimmy A. Light; Charles E. L. B. Davis; Emily A. Blumberg; David K. Simon; Aruna K. Subramanian; J. Michael Millis; G. Marshall Lyon; Kenneth L. Brayman; Doug Slakey; Ron Shapiro; Joseph K. Melancon; Jeffrey M. Jacobson; Valentina Stosor; Jean L. Olson; Donald Stablein; Michelle E. Roland

BACKGROUND The outcomes of kidney transplantation and immunosuppression in people infected with human immunodeficiency virus (HIV) are incompletely understood. METHODS We undertook a prospective, nonrandomized trial of kidney transplantation in HIV-infected candidates who had CD4+ T-cell counts of at least 200 per cubic millimeter and undetectable plasma HIV type 1 (HIV-1) RNA levels while being treated with a stable antiretroviral regimen. Post-transplantation management was provided in accordance with study protocols that defined prophylaxis against opportunistic infection, indications for biopsy, and acceptable approaches to immunosuppression, management of rejection, and antiretroviral therapy. RESULTS Between November 2003 and June 2009, a total of 150 patients underwent kidney transplantation; survivors were followed for a median period of 1.7 years. Patient survival rates (±SD) at 1 year and 3 years were 94.6±2.0% and 88.2±3.8%, respectively, and the corresponding mean graft-survival rates were 90.4% and 73.7%. In general, these rates fall somewhere between those reported in the national database for older kidney-transplant recipients (≥65 years) and those reported for all kidney-transplant recipients. A multivariate proportional-hazards analysis showed that the risk of graft loss was increased among patients treated for rejection (hazard ratio, 2.8; 95% confidence interval [CI], 1.2 to 6.6; P=0.02) and those receiving antithymocyte globulin induction therapy (hazard ratio, 2.5; 95% CI, 1.1 to 5.6; P=0.03); living-donor transplants were protective (hazard ratio, 0.2; 95% CI, 0.04 to 0.8; P=0.02). A higher-than-expected rejection rate was observed, with 1-year and 3-year estimates of 31% (95% CI, 24 to 40) and 41% (95% CI, 32 to 52), respectively. HIV infection remained well controlled, with stable CD4+ T-cell counts and few HIV-associated complications. CONCLUSIONS In this cohort of carefully selected HIV-infected patients, both patient- and graft-survival rates were high at 1 and 3 years, with no increases in complications associated with HIV infection. The unexpectedly high rejection rates are of serious concern and indicate the need for better immunotherapy. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT00074386.).


American Journal of Transplantation | 2008

HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes.

Michelle E. Roland; Burc Barin; Laurie Carlson; Lynda Frassetto; Norah A. Terrault; Ryutaro Hirose; Chris E. Freise; Leslie Z. Benet; Nancy L. Ascher; John P. Roberts; Barbara Murphy; M. J. Keller; Kim M. Olthoff; Emily A. Blumberg; Kenneth L. Brayman; S. T. Bartlett; Charles E. L. B. Davis; J. M. McCune; B. M. Bredt; Donald Stablein; Peter G. Stock

Improvements in human immunodeficiency virus (HIV)‐associated mortality make it difficult to deny transplantation based upon futility. Outcomes in the current management era are unknown. This is a prospective series of liver or kidney transplant recipients with stable HIV disease. Eleven liver and 18 kidney transplant recipients were followed for a median of 3.4 years (IQR [interquartile range] 2.9–4.9). One‐ and 3‐year liver recipients’ survival was 91% and 64%, respectively; kidney recipients’ survival was 94%. One‐ and 3‐year liver graft survival was 82% and 64%, respectively; kidney graft survival was 83%. Kidney patient and graft survival were similar to the general transplant population, while liver survival was similar to the older population, based on 1999–2004 transplants in the national database. CD4+ T‐cell counts and HIV RNA levels were stable; and there were two opportunistic infections (OI). The 1‐ and 3‐year cumulative incidence (95% confidence intervals [CI]) of rejection episodes for kidney recipients was 52% (28–75%) and 70% (48–92%), respectively. Two‐thirds of hepatitis C virus (HCV)‐infected patients, but no patient with hepatitis B virus (HBV) infection, recurred. Good transplant and HIV‐related outcomes among kidney transplant recipients, and reasonable outcomes among liver recipients suggest that transplantation is an option for selected HIV‐infected patients cared for at centers with adequate expertise.


Liver Transplantation | 2013

Long‐term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation

Michael R. Lucey; Norah A. Terrault; Lolu Ojo; J. Eileen Hay; James Neuberger; Emily A. Blumberg; Lewis Teperman

Michael R. Lucey, Norah Terrault, Lolu Ojo, J. Eileen Hay, James Neuberger, Emily Blumberg, and Lewis W. Teperman Division of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI; Gastroenterology Division, Department of Medicine, University of California San Francisco, San Francisco, CA; Division of Nephrology, Department of Medicine, University of Michigan, Ann Arbor, MI; Mayo Clinic, Rochester, MN; Liver Unit, Queen Elizabeth Hospital, Birmingham, United Kingdom; Division of Infectious Diseases, University of Pennsylvania School of Medicine, Philadelphia, PA; and Department of Surgery, NYU Transplant Associates, New York, NY


The Journal of Infectious Diseases | 2004

Absence of Cytomegalovirus-Resistance Mutations after Valganciclovir Prophylaxis, in a Prospective Multicenter Study of Solid-Organ Transplant Recipients

Guy Boivin; Nathalie Goyette; Christian Gilbert; Noel Allan Roberts; Katherine Macey; Carlos V. Paya; Mark D. Pescovitz; Atul Humar; Ed Dominguez; Kenneth Washburn; Emily A. Blumberg; Barbara D. Alexander; Richard B. Freeman; Nigel Heaton; Emma Covington

We investigated the emergence of cytomegalovirus (CMV) ganciclovir-resistance mutations in 301 high-risk solid-organ transplant (SOT) recipients after oral prophylaxis, for 100 days, with either valganciclovir or ganciclovir. For patients treated with ganciclovir, the incidence of CMV UL97 mutations was 1.9% (2/103) at the end of prophylaxis and 6.1% (2/33) for patients with suspected CMV disease up to 1 year after transplantation. No resistance mutations were detected in samples from valganciclovir-treated patients. Dual polymerase (UL54) and UL97 resistance mutations were not seen. Valganciclovir was associated with negligible risk of resistance and thus constitutes a useful alternative to ganciclovir prophylaxis for CMV in high-risk SOT recipients.


American Journal of Transplantation | 2003

The Report of a National Conference on the Wait List for Kidney Transplantation

Robert S. Gaston; Gabriel M. Danovitch; Patricia L. Adams; James J. Wynn; Robert M. Merion; Mark H. Deierhoi; Robert A. Metzger; J. Michael Cecka; William E. Harmon; Alan B. Leichtman; Aaron Spital; Emily A. Blumberg; Charles A. Herzog; Robert A. Wolfe; Dolly B. Tyan; John Roberts; Richard J. Rohrer; Friedrich K. Port; Francis L. Delmonico

In March, 2002, over 100 members of the transplant community assembled in Philadelphia for a meeting designed to address problems associated with the growing number of patients seeking kidney transplantation and added to the waiting list each year. The meeting included representatives of nine US organizations with interests in these issues. Participants divided into work groups addressing access to the waiting list, assigning priority on the list, list management, and identifying appropriate candidates for expanded criteria donor kidneys. Each work group outlined problems and potential remedies within each area. This report summarized the issues and recommendations regarding the waiting list for kidney transplantation addressed in the Philadelphia meeting.


American Journal of Transplantation | 2009

Donor‐Derived Disease Transmission Events in the United States: Data Reviewed by the OPTN/UNOS Disease Transmission Advisory Committee

Michael G. Ison; J. Hager; Emily A. Blumberg; J. Burdick; K. Carney; J. Cutler; J. M. Dimaio; R. Hasz; Matthew J. Kuehnert; E. Ortiz-Rios; Lewis Teperman; Michael A. Nalesnik

Donor‐derived disease transmission is increasingly recognized as a source of morbidity and mortality among transplant recipients. Policy 4.7 of the Organ Procurement and Transplantation Network (OPTN) currently requires reporting of donor‐derived events. All potential donor‐derived transmission events (PDDTE) reported to OPTN/UNOS were reviewed by the Disease Transmission Advisory Committee (DTAC). Summary data from January 1, 2005–December 31, 2007, were prepared for presentation. Reports of PDDTE have increased from 7 in 2005, the first full year data were collected, to 60 in 2006 and to 97 in 2007. More detailed information is available for 2007; a classification system for determining likelihood of donor‐derived transmission was utilized. In 2007, there were four proven and one possible donor‐derived malignancy transmissions and four proven, two probable and six possible donor‐derived infectious diseases transmissions. There were nine reported recipient deaths attributable to proven donor transmissions events arising from eight donors during 2007. Although recognized transmission events resulted in significant morbidity and mortality, transmission was reported in only 0.96% of deceased donor donations overall. Improved reporting, through enhanced recognition and communication, will be critical to better estimate the transmission risk of infection and malignancy through organ transplantation.


The Journal of Infectious Diseases | 2009

Zygomycosis in Solid Organ Transplant Recipients: A Prospective, Matched Case-Control Study to Assess Risks for Disease and Outcome

Nina Singh; José María Aguado; Hugo Bonatti; Graeme N. Forrest; Krishan L. Gupta; Nasia Safdar; George T. John; Kenneth Pursell; Patricia Muñoz; Robin Patel; Jesús Fortún; Pilar Martín-Dávila; Bruno Philippe; François Philit; Alexis Tabah; Nicolas Terzi; Valérie Chatelet; Shimon Kusne; Nina M. Clark; Emily A. Blumberg; Marino Blanes Julia; Abhi Humar; Sally Houston; Cornelia Lass-Flörl; Leonard B. Johnson; Erik R. Dubberke; Michelle A. Barron; Olivier Lortholary

BACKGROUND Clinical characteristics, risks, and outcomes in solid organ transplant (SOT) recipients with zygomycosis in the era of modern immunosuppressive and newer antifungal agent use have not been defined. METHODS In a matched case-controlled study, SOT recipients with zygomycosis were prospectively studied. The primary outcome measure was success (complete or partial response) at 90 days. RESULTS Renal failure (odds ratio [OR], 3.17; P = .010), diabetes mellitus (OR, 8.11; P < .001), and prior voriconazole and/or caspofungin use (OR, 4.41; P = .033) were associated with a higher risk of zygomycosis, whereas tacrolimus (OR, 0.23; P = .002) was associated with a lower risk of zygomycosis. Liver transplant recipients were more likely to have disseminated disease (OR, 5.48; P = .021) and developed zygomycosis earlier after transplantation than did other SOT recipients (median, 0.8 vs 5.7 months; P < .001). Overall the treatment success rate was 60%. Renal failure (OR, 11.3; P = .023) and disseminated disease (OR, 14.6; P = .027) were independently predictive of treatment failure, whereas surgical resection was associated with treatment success (OR, 33.3; P = .003). The success rate with liposomal amphotericin B was 4-fold higher even when controlling for the aforementioned variables. CONCLUSIONS The risks identified for zygomycosis and for disseminated disease, including those that were previously unrecognized, have implications for further elucidating the biologic basis and for optimizing outcomes in SOT recipients with zygomycosis.


Transplantation | 2010

Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: Two-year results of the impact study

Atul Humar; Ajit P. Limaye; Emily A. Blumberg; Ingeborg A. Hauser; Flavio Vincenti; Alan G. Jardine; Daniel Abramowicz; Jane Ives; Mahdi Farhan; Patrick Peeters

Background. Whether the early reduction in cytomegalovirus (CMV) disease seen at 1 year with prolongation of antiviral prophylaxis (up to 200 days) persists in the long term is unknown. Methods. This international, randomized, prospective, double-blind study, compared 318 CMV D+/R− kidney transplant recipients receiving valganciclovir (900 mg) once daily for up to 200 days vs. 100 days. Long-term outcomes including CMV disease, acute rejection, graft loss, patient survival, and seroconversion were assessed. Results. At 2 years posttransplant, CMV disease occurred in significantly less patients in the 200- vs. the 100-day group: 21.3% vs. 38.7%, respectively (P<0.001). Between year 1 and 2, there were only 10 new cases of CMV disease; 7 in the 200-day group and 3 in the 100-day group. Patient survival was 100% in the 200-day group and 97% in the 100-day group (p=not significant). Biopsy-proven acute rejection and graft loss rates were comparable in both groups (11.6% vs. 17.2%, P=0.16, and 1.9% vs. 4.3%, P=0.22, in the 200-day vs. 100-day groups, respectively). Seroconversion was delayed in the 200-day group but was similar to the 100-day group by 2 years posttransplant (IgM or IgG seroconversion; 55.5% in the 200-day group vs. 62.0% in the 100-day group at 2-years; P=0.26). Assessment of seroconversion at the end of prophylaxis was of limited utility for predicting late-onset CMV disease. Conclusion. Extending valganciclovir prophylaxis from 100 to 200 days is associated with a sustained reduction in CMV disease up to 2 years posttransplant.

Collaboration


Dive into the Emily A. Blumberg's collaboration.

Top Co-Authors

Avatar

Roy D. Bloom

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Atul Humar

University Health Network

View shared research outputs
Top Co-Authors

Avatar

Peter G. Stock

University of California

View shared research outputs
Top Co-Authors

Avatar

Peter L. Abt

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Peter P. Reese

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ajit P. Limaye

University of Washington

View shared research outputs
Top Co-Authors

Avatar

Deirdre Sawinski

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Michael Green

University of Pittsburgh

View shared research outputs
Top Co-Authors

Avatar

Robin K. Avery

Johns Hopkins University

View shared research outputs
Researchain Logo
Decentralizing Knowledge